Considerations when selecting a genomic test to use in specific breast cancer patients

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explains that the use of genomic tests for breast cancer patients in clinical practice is affected by numerous factors, including the ability of the test to predict response to treatment and the ability of the test to provide meaningful prognostic information in addition to the information provided by clinicopathologic tools.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:
Color/Sound:

2015
02:01
Color/Sound

Comments are closed.